Macular degeneration cannot be fully reversed with any current treatment. There is no cure for either the dry or wet form of the disease. However, that answer deserves important context: certain treatments for wet macular degeneration can partially restore lost vision in some patients, newer drugs can slow the progression of advanced dry disease, and low-vision tools can dramatically improve how well you function day to day. The distinction between “reversing the disease” and “recovering usable vision” matters a great deal.
What Wet AMD Treatment Can Actually Achieve
Wet age-related macular degeneration (AMD) is the form where abnormal blood vessels leak fluid beneath the retina. It progresses quickly but also responds best to treatment. The standard approach involves injections of a drug that blocks the growth signal driving those abnormal vessels. These injections can sometimes improve your vision, not just stabilize it.
In the landmark ANCHOR and MARINA studies, patients receiving monthly injections improved by several lines on the eye chart. A five-year follow-up of a large clinical trial found that 50% of patients maintained 20/40 vision or better in the treated eye, which is sharp enough to drive in most states. About 30% fell somewhere in the middle range, and 20% had 20/200 or worse. So while the treatment works well for many people, outcomes vary widely, and the gains require ongoing injections. Even with successful treatment, symptoms often return if therapy is paused or stopped.
The key takeaway: wet AMD treatment can recover some vision you’ve already lost, but it’s not a reversal of the underlying disease. The abnormal blood vessels can regrow, and the retina may sustain permanent damage over time.
Slowing Advanced Dry AMD
Dry AMD is far more common and, until recently, had no approved treatments at all. The advanced stage, called geographic atrophy, involves patches of retinal cells that gradually die. Once those cells are gone, the vision loss in that area is permanent. No drug currently restores it.
Two newer medications target the immune pathway that drives this cell death. In clinical trials, one reduced the rate at which the damaged area expanded by up to 31% compared to no treatment, while the other reduced growth by about 19% at the two-year mark, with the effect increasing over time. These are meaningful slowdowns, but they do not stop progression entirely, and they cannot bring back vision in areas already affected. For many patients, slowing the spread by even a third can mean years of preserved central vision that would otherwise be lost.
Supplements and the 25% Risk Reduction
If you have intermediate dry AMD, a specific supplement formula can reduce your risk of progressing to the advanced, vision-threatening stage by about 25%. This formula, known as AREDS2, contains vitamin C, vitamin E, zinc, copper, lutein, and zeaxanthin. It was developed through large clinical trials sponsored by the National Eye Institute.
The supplements don’t reverse any existing damage, and they don’t help people who already have advanced AMD or those with only early-stage disease. They occupy a specific and important role: protecting the window of usable vision for people in that middle stage. If your eye doctor has told you that you have intermediate AMD, this is one of the most concrete steps you can take.
Why Smoking Matters More Than You’d Expect
Current smokers face roughly double the odds of developing AMD compared to people who have never smoked. That elevated risk applies to both the dry and wet forms. The encouraging finding is that quitting makes a real difference: people who stopped smoking more than 20 years ago had risk levels statistically indistinguishable from nonsmokers. Even quitting less than 20 years ago brought the odds down noticeably compared to continuing. If you smoke and have early or intermediate AMD, stopping is one of the few things proven to meaningfully lower your chances of progression.
Monitoring for the Dry-to-Wet Shift
About 10 to 15% of people with dry AMD eventually convert to the wet form. Catching that shift early is critical because wet AMD treatment works best when started before significant damage occurs. The classic home test is the Amsler grid, a printed square of lines you check for distortion. It’s simple and free, but it has low sensitivity and many people don’t use it consistently.
Digital home monitoring devices exist as an alternative, but real-world performance has been mixed. At one clinical site, over 93% of the alerts generated by a digital monitor turned out to be false positives, and several eyes that did convert to wet AMD were missed entirely. Regular eye exams with retinal imaging remain the most reliable way to catch conversion early. Your doctor uses detailed scans that can detect fluid buildup beneath the retina before you notice any change in your vision.
Low-Vision Tools That Restore Function
Even when the disease itself can’t be reversed, the functional impact of vision loss can be substantially reduced. Low-vision rehabilitation uses a combination of optical and electronic devices to help you read, watch television, recognize faces, and manage daily tasks independently.
The most commonly helpful tools include high-powered reading glasses that leave your hands free, handheld magnifiers for reading labels and bills, stand magnifiers for longer reading sessions, and portable video magnifiers that can enlarge text up to 25 times with adjustable contrast. In studies of people with AMD, the majority showed statistically significant improvement in near vision when using these devices. More than half of patients benefited most from high-powered reading glasses, while younger patients tended to prefer handheld magnifiers and older patients favored hands-free options.
Simple environmental changes also help: increasing lighting (especially for reading), enhancing contrast on screens and surfaces, and reorganizing living spaces to reduce dependence on fine detail vision. These modifications won’t change what your eye chart score is, but they can change whether you can read your mail, cook a meal, or continue working.
Gene Therapy and Stem Cells on the Horizon
True reversal of macular degeneration would require regenerating dead retinal cells or permanently eliminating the need for repeated injections. Both goals are being pursued in clinical trials, though neither is available as a standard treatment yet.
Gene therapy aims to deliver a one-time treatment that causes your own eye cells to continuously produce the protein that blocks abnormal blood vessel growth, potentially replacing monthly or bimonthly injections for wet AMD. In early trials, one approach left 73% of participants free of any additional injections, and another reduced injection frequency by 80 to 98% over two years. Visual acuity remained stable in these patients. These therapies are still being tested in larger trials, but the results so far suggest that a single treatment could eventually maintain the benefits currently requiring dozens of injections over a lifetime.
Stem cell therapy takes a more ambitious approach: replacing the retinal pigment cells that die in dry AMD. Researchers have made significant progress in growing these cells from stem cells in the lab, and initial clinical trials have shown the approach to be safe with signs of potential benefit. Combinations of stem cells with gene editing tools are also being explored. This work is still in early stages, but it represents the closest thing to a true reversal strategy currently under investigation.